Diabetic Retinopathy

Primary Care - Clinics in Office Practice

Volumn 42, Issue 3, 2015, Pages 451-464

  Hendrick, Andrew M ^a   Gibson, Maria V ^b   Kulshreshtha, Ambar ^b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetic retinopathy; Glycemic control; Nonproliferative diabetic retinopathy; Proliferative diabetic retinopathy; Visual impairment

Indexed keywords

ACETYLSALICYLIC ACID; ANESTHETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; HEMOGLOBIN A1C; TRIAMCINOLONE; TROPICAMIDE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; ANTITHROMBOCYTIC AGENT; GLUCOSE BLOOD LEVEL;

BLINDNESS; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DYSLIPIDEMIA; ECHOOCULOGRAPHY; EXERCISE; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IRIS DISEASE; LASER COAGULATION; NEOVASCULARIZATION (PATHOLOGY); NEOVASCULARIZATION OF THE IRIS; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PATIENT REFERRAL; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; PROLIFERATIVE DIABETIC RETINOPATHY; RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA ISCHEMIA; REVIEW; SCREENING; SMOKING; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS HEMORRHAGE; DYSLIPIDEMIAS; GLUCOSE BLOOD LEVEL; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MASS SCREENING; PRIMARY HEALTH CARE; QUALITY OF LIFE; RISK FACTOR;

ADRENAL CORTEX HORMONES; ANGIOGENESIS INHIBITORS; BLOOD GLUCOSE; DIABETIC RETINOPATHY; DYSLIPIDEMIAS; EXERCISE; HUMANS; HYPERTENSION; INTRAVITREAL INJECTIONS; LIGHT COAGULATION; MACULAR EDEMA; MASS SCREENING; PLATELET AGGREGATION INHIBITORS; PREVALENCE; PRIMARY HEALTH CARE; QUALITY OF LIFE; REFERRAL AND CONSULTATION; RISK FACTORS; SMOKING; VITRECTOMY;

EID: 84940213947     PISSN: 00954543     EISSN: 1558299X     Source Type: Journal    
DOI: 10.1016/j.pop.2015.05.005     Document Type: Review

References (30)

1. ADA. National Diabetes Statistics Report, 2014. 2014. Accessed October 2, 2014. http://www.diabetes.org/diabetes-basics/statistics/.
2. Saaddine J.B., Honeycutt A.A., Narayan K.M., et al. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. Arch Ophthalmol 2008, 126(12):1740-1747.
3. Klein R., Klein B.E., Moss S.E., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984, 102:520-526.
4. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UK Prospective Diabetes Study Group. BMJ 1998, 317:708-713.
5. Bandello F., Lattanzio R., Zucchiatti I., et al. Pathophysiology and treatment of diabetic retinopathy. Acta Diabetol 2013, 50(1):1-20.
6. Antonetti D.A., Klein R., Gardner T.W. Mechanisms of disease diabetic retinopathy. N Engl J Med 2012, 366:1227-1239.
7. Tarr J.M., Kaul K., Chopra M., et al. Pathophysiology of diabetic retinopathy. Ophthalmology 2013, 2013:1-13.
8. Zhang X., Saadine J., Chou C.F., et al. Prevalence of diabetic retinopathy in the U.S 2004-2008. JAMA 2010, 204(6):649-656.
9. NIH National Eye Institute. Diabetic eye disease, statistics and data [NEI]. 2010. Available at: . Accessed September 26, 2014. https://www.nei.nih.gov/eyedata/diabetic.asp.
10. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 1. Arch Ophthalmol 1985, 103:1796-1806.
11. Van Leiden H.A., Dekker J.M., Moll A.C., et al. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn Study. Diabetes Care 2002, 25(8):1320-1325.
12. Klein R., Moss S.E., Klein B.E. Is gross proteinuria a risk factor for the incidence of proliferative diabetic retinopathy?. Ophthalmology 1993, 100(8):1140-1146.
13. Cruickshanks K.J., Ritter L.L., Klein R., et al. The association of microalbuminuria with diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 1993, 100(6):862-867.
14. Klein B.E., Moss S.E., Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990, 13(1):34-40.
15. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002, 287(19):2563-2569.
16. Chew E.Y., Ambrosius W.T., Davis M.D., ACCORD Study Group, ACCORD Eye Study Group, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010, 363(3):233-244.
17. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366(9500):1849-1861.
18. Rodriguez-Fontal M., Kerrison J.B., Alfaro D.V., et al. Metabolic control and diabetic retinopathy. Curr Diabetes Rev 2009, 5(1):3-7.
19. ADA Standards of medical care in diabetes-2014. Diabetes Care 2014, 37(Suppl 1):S14-S80.
20. Mühlauser I., Sawicki P., Berger M. Cigarette smoking as a risk factor for macroproteinuria and proliferative retinopathy in type 1(insulin-dependent) diabetes. Diabetologia 1986, 29:500-502.
21. Mühlhauser I., Bender R., Bott U., et al. Cigarette smoking and progression of retinopathy and nephropathy in type 1 diabetes. Diabet Med 1996, 13:536-543.
22. Albert S.G., Bernbaum M. Exercise for patients with diabetic retinopathy. Diabetes Care 1995, 18(1):130-132.
23. The Diabetes Control and Complications Trial Research Group Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 2000, 23(8):1084-1091.
24. Early treatment diabetic retinopathy study design and baseline patient characteristics. Ophthalmology 1991, 98(5 Suppl):741-756.
25. Sivak-Callcott J.A., O'Day D.M., Gass J.D., et al. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 2001, 108(10):1767-1776.
26. Bressler N.M., Edwards A.R., Beck R.W., et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol 2013, 131(8):1033-1040.
27. Diabetic Retinopathy Clinical Research Network Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011, 118(4):609-614.
28. Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1. Ophthalmology 1985, 92(4):492-502.
29. Diabetic Retinopathy Study Research Group Photocoagulation treatment of proliferative diabetic retinopathy. Clinical applications of diabetic retinopathy study (DRS) findings, DRS report number 8. Ophthalmology 1981, 88:583-600.
30. Canadian Ophthalmological Society Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. Can J Ophthalmol 2012, 47:S1-S30.